Trends in medication management. - TELUS Health...2. How generic substitution is deployed can have a...
Transcript of Trends in medication management. - TELUS Health...2. How generic substitution is deployed can have a...
#HealthBenefitsTrends
Trends in medicationmanagement.
Vishal Ravikanti R.Ph
Manager, Professional Services, TELUS Health
2#HealthBenefitsTrends
Content outlinei. Therapy class insights 2018
ii. Legislative update
iii. Biosimilars & subsequent entry products
iv. Drug pipeline
Therapy class insights
2018
4#HealthBenefitsTrends
Top 10 drug classes by adjudicated amountOntario
Therapeutic class
Rank by total
adjudicated amount
Percent of total
adjudicated amount
2018 2017 2018 2017
Diabetes 1 2 11.7% 10.3%
Rheumatoid arthritis 2 1 10.9% 11.1%
Skin disorders 3 3 6.5% 5.6%
Cancer 4 5 6.0% 4.9%
Asthma 5 4 5.4% 5.6%
Depression 6 7 4.3% 4.6%
Blood pressure 7 6 4.2% 4.7%
Ulcers 8 8 3.7% 3.8%
Cholesterol disorders 9 9 3.2% 3.4%
Multiple sclerosis 10 13 3.1% 2.8%
% of total adjudicated amount 59% 56.8%
5#HealthBenefitsTrends
Top 10 products by adjudicated amountOntario
Drug name
Rank by total
adjudicated amount
Percent of total
adjudicated amount
2018 2017 2018 2017
Remicade 1 1 3.7% 4.3%
Humira 2 2 3.5% 3.4%
Insulin 3 3 1.8% 2.0%
Stelara 4 7 1.7% 1.3%
Enbrel 5 4 1.4% 1.6%
Crestor 6 5 1.4% 1.5%
Nexium 7 6 1.4% 1.4%
Janumet 8 10 1.1% 1.0%
Victoza 9 13 0.9% 0.9%
Symbicort 10 12 0.9% 0.9%
% of adjudicated amount 17.8% 18.3%
6#HealthBenefitsTrends
Therapy class insights
Diabetes
What is happening outside of the top 10?
Impact of generic substitution type
Therapeutic class
Rank by total
adjudicated amount
Percent of total
adjudicated amount
2018 2017 2018 2017
HIV 16 14 1.9% 2.2%
Migraine 25 28 1.2% 1.1%
7#HealthBenefitsTrends
$990
$839 $1,213
0 $
5,000,000 $
10,000,000 $
15,000,000 $
20,000,000 $
25,000,000 $
30,000,000 $
35,000,000 $
40,000,000 $
45,000,000 $
50,000,000 $
2014 2015 2016 2017 2018
INSULIN CLASS -14,6% JANUMET 19,3% JARDIANCE 88,1%
GLP1 CLASS 32,2% INVOKANA -13,7% FREESTYLE LIBRE 2160 %
Total eligible cost 2018: $221 M (+10,1 %)
$1,693
Diabetes: Trends in medication use
$907 $728
To
tal e
ligib
le c
osts
-O
nta
rio
Suggested management: step therapy
8#HealthBenefitsTrends
97%91%
0%
20%
40%
60%
80%
100%
Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018
Generic Truvada
Generic Viread
Generic Atripla
Number of claimants (Ontario)
Outside the top 10: New HIV generics
1 902
1 237
159
Generi
c u
tiliz
ation
(Onta
rio)
Health Canada
approved generics
Suggested management: generic substitution
9#HealthBenefitsTrends
100 $
125 $
150 $
175 $
200 $
Jan 2018 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan-19 Feb
Triptan Only Total Migraine
November 2018: First CGRP inhibitor claim on TELUS BoB
Outside the top 10: Migraine – impact of new entrant A
ve
rage e
ligib
le c
ost p
er
cla
ima
nt
(On
tario)
$147
$156
Suggested management: prior authorization / generic substitution / managed formulary
10#HealthBenefitsTrends
0 $
200 $
400 $
None Regular Mandatory
Brand Crestor Generic Crestor
$135
$27
$412
Impact of generic substitution type – Crestor A
ve
rage e
ligib
le c
ost p
er
cla
ima
nt
(On
tario)
Generic substitution type
Suggested management: mandatory generic substitution
Legislative update
12#HealthBenefitsTrends
National pharmacare
Advisory council introduced
February
2018
Finance Minister Morneau speech
House of commons
report
Advisory council consultation sessions & townhalls
Interim report from the advisory
council & federal budget released
Advisory council’s final
report anticipated
March
2018
April
2018
July-
October
2018
March
2019
Spring
2019
13#HealthBenefitsTrends
National pharmacare
Interim report & budget 2019
Foundational recommendations for national pharmacare
1. Creation of a national drug agency: Canadian Drug Agency
2. Comprehensive, evidence-based national formulary
3. Invest in drug data and information technology (IT) systems
4. National strategy for high cost drugs for rare diseases
14#HealthBenefitsTrends
OHIP+: program changes
As of April 1, 2019 eligibility changes for OHIP+ have taken effect.
Children and youth, 24 years of age and under, are no longer eligible for
OHIP+ if they are covered by a private insurance plan.
Prior authorization transition plan.
What can we expect going forward?
15#HealthBenefitsTrends
$0
$4,000,000
$8,000,000
$12,000,000
$16,000,000
$20,000,000
$24,000,000
Jan2017
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2018
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
OHIP+ implementation Total 2017 : $244.6M
Total 2018 : $121.9M
OHIP+: pre & post implementation T
ota
l e
ligib
le c
osts
Biosimilars & subsequent
entry products
17#HealthBenefitsTrends
National uptake - TELUS BoB experience
Biosimilar brand name(chemical entity; reference brand)
Price
difference vs.
reference
drug
% of claimants % of total eligible cost
2016 2017 2018 2016 2017 2018
GRASTOFIL(filgrastim; Neupogen)
-17% 0.96% 31.34% 57.82% 0.40% 23.66% 49.27%
INFLECTRA(infliximab; Remicade)
-46% 0.84% 3.83% 8.12% 0.36% 1.48% 3.94%
BRENZYS & ERELZI (etanercept; Enbrel)
-37% 0.09% 2.70% 9.24% 0.01% 1.00% 4.53%
BASAGLAR(insuline glargine; Lantus)
-25% 0.56% 1.66% 3.97% 0.22% 0.76% 1.93%
GLATECT(glatiramer; Copaxone)
-29% - - 2.27% - - 0.69%
18#HealthBenefitsTrends
Market share of infliximab
Inflectra, Renflexis - Ontario
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
Jan2016
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2017
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2018
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
% of claimants % of total eligible cost
Inflectra added to ODB
(limited use benefit)
Renflexis added to ODB
(limited use benefit)
6.87%
* Renflexis (infliximab) : 1st claim in December 2018
Ma
rke
t sh
are
(O
nta
rio
)
19#HealthBenefitsTrends
Market share of insulin glargine
Basaglar – Ontario
0.0%
1.0%
2.0%
Jan2016
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2017
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2018
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
% of claimants % of total eligible costBasaglar added to ODB
(general benefit)
Ma
rke
t sh
are
(O
nta
rio
)
2.05%
20#HealthBenefitsTrends
Market share of insulin glargine
Basaglar/Toujeo – Ontario
0%
5%
10%
15%
20%
Jan2016
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2017
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan2018
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Basaglar Toujeo
Ma
rke
t sh
are
(O
nta
rio
)
20.3%
2.05%
21#HealthBenefitsTrends
Update: biosimilars under reviewExpected launches within the next 3 years
Reference medication Indication(s) Health Canada regulatory status Eligible amount
TELUS BoB 2018
Humira (adalimumab)Rheumatoid arthritis/
inflammatory conditions 1 currently under review - November 2018 $177M
Neupogen (filgrastim) Neutropenia 2 currently under review - April 2018$7.8M (originator)
$9.4M (biosimilar)
Avastin (bevacizumab) Cancer (multiple indications) 2 currently under review - August 2018 $4.2M
Herceptin (trastuzumab) Breast cancer / gastric cancer 7 currently under review - February 2018 $114K
Rituxan (rituximab)
Lymphoma / leukemia /
rheumatoid arthritis / GPA &
MPA
4 currently under review - April 2018 $10.9M
Forteo (teriparatide) Osteoporosis 1 currently under review - June 2018 $2.7M
>$212M
Drug pipeline
23#HealthBenefitsTrends
Biosimilar pipeline
Generic submissions (40 molecules)
Novel oral anticoagulants (Xarelto, Eliquis, Pradaxa)
Multiple sclerosis (Gilenya & Fampyra)
132 submissions (new drugs & new indications)
1/3 are cancer products
New biologics (migraine, osteoporosis)
Expansion of indications
Submissions under review – Health Canada
Cost
drivers
Cost
relief
24#HealthBenefitsTrends
New drug pipeline – short-term
Drug Indication Potential impact Cost
larotrectinib
Bayer
A kinase inhibitor targeted against solid tumors testing positive
for a mutation known as an NTRK gene fusion.
FDA approval in December 2018 (Vitrakvi) as a tumor
agnostic drug.
Submitted to Health Canada in November 2018
Oral cancer treatment, therefore will
impact private payers. New
paradigm in approval of oncology
products without a specific cancer
type.
U.S. pricing set
between $11,000
and $32,800 per
month (pediatric
and adult dosing).
ataluren
PTC therapeutics
(Europe)
Approved in Europe for the treatment of Duchenne muscular
dystrophy caused by a nonsense mutation.
Submitted to Health Canada in September 2018
Sold as TRANSLARNA in Europe
Would be first treatment approved
by Health Canada for specific
subset of Duchenne muscular
dystrophy.
Rare disease
pricing expected.
galcanezumab
Eli Lilly
Monoclonal antibody (biologic drug) targeting CGRP indicated
for the prevention of chronic and episodic migraines.
Submitted to Health Canada in October 2018
Aimovig (Novartis) submitted to Health Canada in October
2017, received NOC August 2018
Highly anticipated new drug class
targeting a highly prevalent medical
condition (approx. 8% of
Canadians).
Expected annual
cost up to $7,000.
25#HealthBenefitsTrends
New indication pipeline – short-term
Drug Indication Potential impact Cost
Dupixent
(dupilumab)
Sanofi-Aventis
Recombinant human IgG4 monoclonal antibody that inhibits
signaling of cytokines involved in atopic disease.
FDA approval for severe asthma indication granted in
October 2018.
Submitted to Health Canada in November 2018
Based on pricing for treatment of
atopic dermatitis, Dupixent would be
a costly alternative to exisiting
biologic alternatives in severe
asthma.
Annual cost
approximately
$30,000.
Keytruda
(pembrolizumab)
Merck
Currently approved in Canada for Melanoma, NSCLC,
Hodgkin Lymphoma, Primary Mediastinal B-cell Lymphoma,
Urothelial Carcinoma.
Submitted to Health Canada from September 2017 to
October 2018
FDA approval for tumor agnostic indication based on
common biomarker rather than tumor type
Traditional treatment indications
based on tumor type potentially
seeking tumor agnostic approval.
New paradigm in approval of
oncology products without a specific
cancer type.
Approximately
$8,800 per
treatment cycle.
26#HealthBenefitsTrends
Summary
1. Therapy classes outside of the top 10 are evolving
2. How generic substitution is deployed can have a large impact
3. National pharmacare: advisory council final report – spring 2019
4. Use of biosimilar and subsequent entry products growing slowly
5. New drugs/indications under review both drive costs and provide relief
#HealthBenefitsTrends